Clinical Trial Update: Natriuretic Peptides and Metabolic Risk in Obesity [EARLY_Phase 1]

View source ↗

Summary

EARLY_PHASE1 trial evaluating natriuretic peptides for metabolic risk in obesity has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperinsulinemia
• Obesity

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Obesity, Hyperinsulinemia | EARLY_Phase 1 | Status: WITHDRAWN